158 related articles for article (PubMed ID: 35863797)
1. Impact of High Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy.
Tomoi Y; Takahara M; Soga Y; Kodama K; Imada K; Hiramori S; Ando K
JACC Cardiovasc Interv; 2022 Jul; 15(14):1466-1476. PubMed ID: 35863797
[TBL] [Abstract][Full Text] [Related]
2. Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication.
Tomoi Y; Yamaji K; Soga Y; Hiramori S; Ando K
J Endovasc Ther; 2019 Jun; 26(3):402-410. PubMed ID: 30873910
[TBL] [Abstract][Full Text] [Related]
3. Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease.
Golledge J; Rowbotham S; Velu R; Quigley F; Jenkins J; Bourke M; Bourke B; Thanigaimani S; Chan DC; Watts GF
J Am Heart Assoc; 2020 Mar; 9(6):e015355. PubMed ID: 32172653
[TBL] [Abstract][Full Text] [Related]
4. Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease.
Lee JH; Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Jang Y
J Vasc Surg; 2016 Mar; 63(3):756-63. PubMed ID: 26603545
[TBL] [Abstract][Full Text] [Related]
5. Association of Statin Therapy With Major Adverse Cardiovascular and Limb Outcomes in Patients With End-stage Kidney Disease and Peripheral Artery Disease Receiving Maintenance Dialysis.
Lo HY; Lin YS; Lin DS; Lee JK; Chen WJ
JAMA Netw Open; 2022 Sep; 5(9):e2229706. PubMed ID: 36048442
[TBL] [Abstract][Full Text] [Related]
6. Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy.
Waissi F; Dekker M; Timmerman N; Hoogeveen RM; van Bennekom J; Dzobo KE; Schnitzler JG; Pasterkamp G; Grobbee DE; de Borst GJ; Stroes ESG; de Kleijn DPV; Kroon J
Stroke; 2020 Oct; 51(10):2972-2982. PubMed ID: 32878565
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy.
Nicholls SJ; Tang WH; Scoffone H; Brennan DM; Hartiala J; Allayee H; Hazen SL
J Lipid Res; 2010 Oct; 51(10):3055-61. PubMed ID: 20601648
[TBL] [Abstract][Full Text] [Related]
8. High Apolipoprotein E Levels Predict Adverse Limb Events in Patients with Peripheral Artery Disease Due to Peripheral Artery Disease Undergoing Endovascular Treatment and On-Statin Treatment.
Fukase T; Dohi T; Kato Y; Chikata Y; Takahashi N; Endo H; Doi S; Nishiyama H; Okai I; Iwata H; Okazaki S; Isoda K; Miyauchi K; Daida H; Minamino T
Int Heart J; 2021 Jul; 62(4):872-878. PubMed ID: 34276016
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients.
Kwon SW; Lee BK; Hong BK; Kim JY; Choi EY; Sung JM; Rhee JH; Park YM; Ma DW; Chung H; Mun HS; Lee SJ; Park JK; Min PK; Yoon YW; Rim SJ; Kwon HM
Int J Cardiol; 2013 Sep; 167(5):1990-4. PubMed ID: 22633779
[TBL] [Abstract][Full Text] [Related]
10. Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention.
Suwa S; Ogita M; Miyauchi K; Sonoda T; Konishi H; Tsuboi S; Wada H; Naito R; Dohi T; Kasai T; Okazaki S; Isoda K; Daida H
J Atheroscler Thromb; 2017 Nov; 24(11):1125-1131. PubMed ID: 28321012
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
Puri R; Ballantyne CM; Hoogeveen RC; Shao M; Barter P; Libby P; Chapman MJ; Erbel R; Arsenault BJ; Raichlen JS; Nissen SE; Nicholls SJ
Atherosclerosis; 2017 Aug; 263():137-144. PubMed ID: 28641153
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of lipoprotein (a) on long-term clinical outcomes in diabetic patients on statin treatment after percutaneous coronary intervention.
Takahashi N; Dohi T; Funamizu T; Endo H; Wada H; Doi S; Kato Y; Ogita M; Okai I; Iwata H; Okazaki S; Isoda K; Miyauchi K; Shimada K
J Cardiol; 2020 Jul; 76(1):25-29. PubMed ID: 32089480
[TBL] [Abstract][Full Text] [Related]
13. Sortilin levels correlate with major cardiovascular events of diabetic patients with peripheral artery disease following revascularization: a prospective study.
Biscetti F; Nardella E; Rando MM; Cecchini AL; Bonadia N; Bruno P; Angelini F; Di Stasi C; Contegiacomo A; Santoliquido A; Pitocco D; Landolfi R; Flex A
Cardiovasc Diabetol; 2020 Sep; 19(1):147. PubMed ID: 32977814
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein aggregation predicts adverse cardiovascular events in peripheral artery disease.
Heffron SP; Ruuth MK; Xia Y; Hernandez G; Äikäs L; Rodriguez C; Öörni K; Berger JS
Atherosclerosis; 2021 Jan; 316():53-57. PubMed ID: 33307457
[TBL] [Abstract][Full Text] [Related]
15. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
[TBL] [Abstract][Full Text] [Related]
16. Circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL) as a novel predictor of clinical outcome after endovascular therapy in patients with peripheral artery disease (PAD).
Takamura TA; Tsuchiya T; Oda M; Watanabe M; Saito R; Sato-Ishida R; Akao H; Kawai Y; Kitayama M; Kajinami K
Atherosclerosis; 2017 Aug; 263():192-197. PubMed ID: 28651186
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.
Gurdasani D; Sjouke B; Tsimikas S; Hovingh GK; Luben RN; Wainwright NW; Pomilla C; Wareham NJ; Khaw KT; Boekholdt SM; Sandhu MS
Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):3058-65. PubMed ID: 23065826
[TBL] [Abstract][Full Text] [Related]
18. Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark: A Nationwide Cohort Study.
Søgaard M; Nielsen PB; Skjøth F; Eldrup N; Larsen TB
Circulation; 2021 Mar; 143(9):907-920. PubMed ID: 33300375
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes.
Gencer B; Rigamonti F; Nanchen D; Vuilleumier N; Kern I; Aghlmandi S; Klingenberg R; Räber L; Auer R; Carballo D; Carballo S; Heg D; Windecker S; Lüscher TF; Matter CM; Rodondi N; Mach F
Eur J Clin Invest; 2019 Jul; 49(7):e13117. PubMed ID: 30937890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
